Sacubitril/valsartan as add-on to standard therapy in patients with heart failure: A randomized controlled trial

doi:10.5493/wjem.v15.i4.111542

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-3)

Sum=0

Dec 20, 2025 (publication date) through Dec 19, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Exp Med. Dec 20, 2025; 15(4): 111542
Published online Dec 20, 2025. doi: 10.5493/wjem.v15.i4.111542

Open in New Tab Full Size Figure Download Figure

Figure 1 CONSORT chart. ACEi: Angiotensin converting enzyme inhibitors; ARB: Angiotensin receptor blocker; BD: Twice daily; MI: Myocardial infarction.

Open in New Tab Full Size Figure Download Figure

Figure 2 Comparison of mean change in N-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein levels at 12 weeks from baseline between the two groups. hs-CRP: High-sensitivity C-reactive protein; NT-pro BNP: N-terminal pro-B-type natriuretic peptide.

Citation: Dhawan R, Mittal R, Kumar A, Laller KS, Gill PS, Rag A, Mittal N. Sacubitril/valsartan as add-on to standard therapy in patients with heart failure: A randomized controlled trial. World J Exp Med 2025; 15(4): 111542
URL: https://www.wjgnet.com/2220-315x/full/v15/i4/111542.htm
DOI: https://dx.doi.org/10.5493/wjem.v15.i4.111542